VCAM1 and Hodgkins lymphoma: Using a mouse model of Hodgkin’s lymphoma, antibody-directed targeting of tTF to VCAM-1 obliterated some vessels, reducing mean tumor volume by 45% after 3 weeks, but was not enough to entirely kill the tumors [17].